Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) EPS (Weighted Average and Diluted) (2024 - 2025)

Xilio Therapeutics' EPS (Weighted Average and Diluted) history spans 2 years, with the latest figure at -$0.11 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 50.0% year-over-year to -$0.11; the TTM value through Sep 2025 reached -$0.63, changed N/A, while the annual FY2024 figure was -$1.09, 60.79% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.11 at Xilio Therapeutics, up from -$0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.11 in Q3 2025 and bottomed at -$0.62 in Q1 2024.